PDF(Pubmed)
Abstract：
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.
摘要：
妇科癌症InterGroup（GCIG）第六届卵巢癌临床研究会议实际上于10月举行，2021年，遵循已发布的共识指南。共识会议的目标是在即将进行的卵巢癌试验的设计要素上实现协调。选择未来研究的重要问题，并确定未满足的需求。所有33个GCIG成员团体都参与了开发，精致,并在四个主题组中采用了20个关于卵巢癌临床研究的声明，包括一线治疗，复发性疾病,疾病亚组，和未来的审判。20份声明中有14份获得一致共识，其余六项声明的一致性超过90%。GCIG小组积极审议后的高接受率证实，共识过程可以在虚拟环境中应用。连同未满足的需求的详细分类，这些共识将促进卵巢癌国际临床研究的协调.
